Dopamine Hydrochloride Injec · #8 of 35 active shortages by FDA posting duration
Brand: DOPAMINE HYDROCHLORIDE
FDA lists Dopamine Hydrochloride Injec as Active Shortage (Hikma Pharmaceuticals USA, Inc.).
Availability on file: Unavailable
Dopamine Hydrochloride Injection: Active Shortage
Unavailable 12 shortage presentations are tracked for this drug. Contact your pharmacist if you are affected.
Shortage Details
- Generic Name
- Dopamine Hydrochloride Injection
- Manufacturer
- Hikma Pharmaceuticals USA, Inc.
- Dosage Form
- Injection
- Presentation
- Dopamine Hydrochloride, Injection, 40 mg/1 mL (NDC 0143-9254-25)
- Package NDC
- 0143-9254-25
Status & Timeline
- Status
- Active Shortage
- Availability
- Unavailable
- First Reported
- Nov 6, 2017
- Last Updated
- Mar 12, 2026
- Therapeutic Category
- Cardiovascular
Row fields from the FDA Drug Shortages database via openFDA.
Shortage Reason
Additional lots will be available in the August 2026 timeframe. Product will be made available as it is released.
Full Drug Profile
dopamine
Side effects, interactions, warnings & more
Nearby, Other Dopamine Shortage Records
Dopamine Hydrochloride Injection
Hospira, Inc., a Pfizer Company
Injection
Dopamine Hydrochloride Injection
Hospira, Inc., a Pfizer Company
Injection
Dopamine Hydrochloride Injection
Hospira, Inc., a Pfizer Company
Injection
Dopamine Hydrochloride Injection
Hospira, Inc., a Pfizer Company
Injection
Dopamine Hydrochloride Injection
Hospira, Inc., a Pfizer Company
Injection
Dopamine Hydrochloride Injection
Hikma Pharmaceuticals USA, Inc.
Injection
FDA reason on file: Additional lots will be available in the August 2026 timeframe. General shortage guidance lives on the tracker hub.